Literature DB >> 19189642

PTEN mutation: many birds with one stone in tumorigenesis.

Weijin Liu1, Yonggang Zhou, Sven N Reske, Changxian Shen.   

Abstract

The PTEN (phosphatase and tensin homolog deleted on chromosome ten) tumor suppressor gene is mutated in a wide range of malignancies and recent studies have demonstrated that PTEN prevents tumorigenesis through multiple mechanisms. PTEN functions as a plasma-membrane lipid phosphatase that antagonizes the PI3K (phosphoinositide 3 kinase)-AKT pathway. PTEN physically and genetically interacts with the central genome guardian p53. PTEN also associates with the centromeric protein CENP-C to maintain centromere integrity and suppresses chromosomal instability from DNA double-strand breaks (DSBs) through transcriptional regulation of Rad51 (radiosensitive yeast mutant 51). Moreover PTEN controls the growth and proliferation of haematopoietic stem cells (HSC) and restrains cells from leukemia in an mTOR (mammalian target of rapamycin) dependent manner. Thus, restoring PTEN functions in cancer cells directly or indirectly holds great promise for cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19189642

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

Review 1.  Signal transduction in cancer.

Authors:  Richard Sever; Joan S Brugge
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

Review 2.  Roles of the PI3K/Akt pathway in Epstein-Barr virus-induced cancers and therapeutic implications.

Authors:  Jiezhong Chen
Journal:  World J Virol       Date:  2012-12-12

3.  VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis.

Authors:  Scott R Silva; Kanika A Bowen; Piotr G Rychahou; Lindsey N Jackson; Heidi L Weiss; Eun Y Lee; Courtney M Townsend; B Mark Evers
Journal:  Int J Cancer       Date:  2011-03-01       Impact factor: 7.396

4.  Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth.

Authors:  Jagannath Pal; Mariateresa Fulciniti; Puru Nanjappa; Leutz Buon; Yu-Tzu Tai; Pierfrancesco Tassone; Nikhil C Munshi; Masood A Shammas
Journal:  Cancer Genomics Proteomics       Date:  2012 Mar-Apr       Impact factor: 4.069

Review 5.  Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth.

Authors:  Arno E Commandeur; Aaron K Styer; Jose M Teixeira
Journal:  Hum Reprod Update       Date:  2015-07-03       Impact factor: 15.610

Review 6.  The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.

Authors:  M R Moniri; L-J Dai; G L Warnock
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

7.  Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1).

Authors:  Yang Jiao; Ke-kang Sun; Lin Zhao; Jia-ying Xu; Li-li Wang; Sai-jun Fan
Journal:  Acta Pharmacol Sin       Date:  2011-12-12       Impact factor: 6.150

8.  Antagonizing pathways leading to differential dynamics in colon carcinogenesis in Shugoshin1 (Sgo1)-haploinsufficient chromosome instability model.

Authors:  Chinthalapally V Rao; Saira Sanghera; Yuting Zhang; Laura Biddick; Arun Reddy; Stan Lightfoot; Wei Dai; Hiroshi Y Yamada
Journal:  Mol Carcinog       Date:  2015-03-14       Impact factor: 4.784

Review 9.  mTORC signaling in hematopoiesis.

Authors:  Xiaomin Wang; Yajing Chu; Weili Wang; Weiping Yuan
Journal:  Int J Hematol       Date:  2016-01-20       Impact factor: 2.490

10.  Evaluation of arginine deiminase treatment in melanoma xenografts using (18)F-FLT PET.

Authors:  Lars Stelter; Simon Fuchs; Achim A Jungbluth; Gerd Ritter; Valerie A Longo; Pat Zanzonico; Nathanael Raschzok; Igor M Sauer; John S Bomalaski; Steven M Larson
Journal:  Mol Imaging Biol       Date:  2013-12       Impact factor: 3.488

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.